newsfilter
← Latest News
GlobeNewswire·

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

  • Zevra Therapeutics, Inc. appointed Alicia Secor to its Board of Directors effective December 2, 2025.
  • Director Wendy Dixon, PhD, retired from the Board effective December 2, 2025.
  • Alicia Secor brings over thirty years of life sciences experience, most recently serving as CEO of Atalanta Therapeutics.
  • Secor previously served as CEO of Juniper Pharmaceuticals from 2016 to 2018 prior to its acquisition by Catalent.
  • From 1998 to 2013, Secor held increasing leadership roles at Genzyme, culminating as Vice President of Metabolic Diseases.
  • Secor previously served on the boards of Orchard Therapeutics, G1 Therapeutics, GW Pharmaceuticals, and the Foundation for Prader-Willi Research.
  • Secor holds an MBA from Northeastern University's D'Amore-McKim School of Business and a BS in Health Administration from the University of New Hampshire.
  • Board Chair Tamara A. Favorito stated Secor's expertise will support Zevra's strategy to deliver value for shareholders.
  • CEO Neil F. McFarlane noted Secor's rare disease leadership complements Zevra's team.
  • Zevra Therapeutics is a commercial-stage company focused on developing therapies for people living with rare diseases.